Clinical HIV Research Unit, Wits Health Consortium, Themba Lethu Clinic, Helen Joseph Hospital, Perth Road, Auckland Park, Johannesburg 2092, South Africa.
Clinical HIV Research Unit, Wits Health Consortium, Themba Lethu Clinic, Helen Joseph Hospital, Perth Road, Auckland Park, Johannesburg 2092, South Africa; Division of Global Women's Health, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, 3009 Old Clinic Building, Campus Box 7577, Chapel Hill, NC, USA.
Obstet Gynecol Clin North Am. 2022 Dec;49(4):771-781. doi: 10.1016/j.ogc.2022.08.008.
Cervical cancer is a leading cause of cancer among women. Approximately 350,000 women die from cervical needlessly from cancer each year, and 85% of the global burden occurs in low- and middle-income countries (LMICs). Disparities in the incidence and mortality between LMICs and industrialized countries can be attributed to differences in access to human papillomavirus (HPV) vaccination and cervical cancer screening and treatment. The World Health Organization (WHO) is leading a renewed international effort to reduce the global burden of cervical cancer. In this article, we discuss recommendations for HPV vaccination, primary HPV screening, and treatment of precancerous lesions.
宫颈癌是女性癌症中的主要病因。每年，约有 35 万名女性不必要地死于宫颈癌，而全球 85%的负担发生在低收入和中等收入国家（LMICs）。LMICs 和工业化国家在发病率和死亡率方面的差异可归因于获得人乳头瘤病毒（HPV）疫苗接种以及宫颈癌筛查和治疗的机会不同。世界卫生组织（WHO）正在领导一项新的国际努力，以减轻全球宫颈癌负担。本文讨论了 HPV 疫苗接种、初级 HPV 筛查和癌前病变治疗的建议。
